Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
CYSTOID MACULAR EDEMA
Interventions
DRUG

Ranibizumab,

Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

DRUG

Triamcinolone acetonide

Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

Trial Locations (1)

19116

Soll Eye, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Soll Eye

OTHER